{
    "patient": {
        "Name": "Omar Hanson",
        "DateOfBirth": "1996-10-02",
        "Sex": "Female",
        "Diagnosis": "Adenocarcinoma",
        "BodyPart": "Pancreatic",
        "Physician": "Dr. Derek Cooley",
        "TreatingInstitution": "Thomas and Sons"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Pancreatic",
            "CollectedDate": "2024-01-26",
            "ReceivedDate": "2024-01-26",
            "TumorPercentage": "56%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-01-29",
            "ReceivedDate": "2024-01-31"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "5.46%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Nonsense-LOF",
                "VariantAlleleFraction": "33.74%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "22.36%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Nonsense-GOF",
                "VariantAlleleFraction": "23.86%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "FGFR2",
            "NCSTN",
            "ERCC2",
            "IKZF1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "23 m/Mb",
            "Tmbpercentile": "63%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "DDR2",
                "DNA Alteration": "c.716T>G",
                "GeneMutation": "p.I638F Frameshift-GOF",
                "VariantAlleleFraction": "13.45%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.2235_2252del18",
                "GeneMutation": "p.G719A Spliceregionvariant-LOF",
                "VariantAlleleFraction": "16.87%"
            },
            {
                "Gene": "DPYD",
                "DNA Alteration": "c.2846A>T",
                "GeneMutation": "p.I543V Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.81%"
            },
            {
                "Gene": "ERBB2",
                "DNA Alteration": "c.2264_2278del",
                "GeneMutation": "p.S310F Frameshift-GOF",
                "VariantAlleleFraction": "1.41%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "5.4%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Stopgain-LOF",
                "VariantAlleleFraction": "4.35%"
            }
        ],
        "Germline": [
            {
                "Gene": "FBXW7",
                "DNA Alteration": "c.1394G>A",
                "GeneMutation": "p.R465H Stopgain-LOF",
                "Condition": "catch"
            }
        ]
    },
    "low coverage regions": [
        "ARID2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Missensevariant(exon2)-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "5.46%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Nonsense-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "33.74%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Missensevariant(exon2)-GOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "22.36%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Nonsense-GOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "23.86%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-01-24"
    },
    "other": {
        "ReportId": "8629",
        "ReportDate": "2024-01-30",
        "SignedBy": "Derek Cooley",
        "Supervisor": "Dr. Karen Allen"
    }
}